Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model
- Haesun Choi MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Imaging technology plays a major role in treatment response assessment in solid tumors and in surveillance for recurrence or progression. Currently available response evaluation criteria, Response Evaluation Criteria in Solid Tumors (RECIST), are based on unidimensional tumor size. Recently, however, these strictly size-based criteria for evaluating responses have been criticized because they do not reflect the biologic changes of solid tumors induced by targeted therapies and thus may be misleading. This problem is evident in response evaluation in advanced gastrointestinal stromal tumor (GIST) treated with a new molecularly targeted agent, imatinib. GISTs can increase in size despite good response to imatinib, and focal progression within a responding GIST can be overlooked with current size-based imaging criteria. Modified objective criteria using a combination of tumor size and density on CT are promising in early response evaluation and in predicting long-term prognosis in patients with advanced GIST treated with imatinib. These criteria may have broad applicability as additional targeted therapies become available to treat solid tumors.
- Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207–214. CrossRef
- Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216. This paper introduces the current Response Evaluation Criteria in Solid Tumour (RECIST) adopted by the European Organization for Research and Treatment of Cancer. It also describes how to choose evaluable lesions and makes specific recommendations on the use of imaging techniques. CrossRef
- Joensuu H, Fletcher C, Dimitrijevic S, et al.: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002, 3:655–664. CrossRef
- Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580. CrossRef
- Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708–710. CrossRef
- Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660–667. CrossRef
- Heinrich MC, Griffith DJ, Druker BJ, et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925–932.
- Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139–145.
- Okuda K, Weisberg E, Gilliland DG, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood 2001, 97:2440–2448. CrossRef
- Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472–480. CrossRef
- van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421–1423. CrossRef
- van Oosterom AT, Judson IR, Verweij J, et al.: Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(Suppl 5):S83-S87. CrossRef
- Verweij J, van Oosterom A, Blay JY, et al.: Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006–2011. CrossRef
- Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127–1134. CrossRef
- Blanke CD, Joensuu H, Demetri GD, et al.: Long-term follow-up of patients with advanced gastrointestinal stromal tumor (GIST) treated with imatinib mesylate [abstract]. Presented at ASCO 2004 Gastrointestinal Cancers Symposium. San Francisco, CA. January 22–24, 2004 [abstract 2].
- Miettinen M, Lasota J: Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001, 438:1–12. CrossRef
- Choi H, Charnsangavej C, Faria Sde C, et al.: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004, 183:1619–1628. This paper reports the response assessment in GIST patients treated with imatinib. Using RECIST underestimates the responses significantly. Other subjective and objective criteria are described and compared with the response shown on FDG-PET.
- Bechtold RE, Chen MY, Stanton CA, et al.: Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 2003, 28:808–814. CrossRef
- Ollivier L: International criteria for tumour assessment. Cancer Imaging 2000, 1:32–34.
- Padhani AR, Ollivier L: The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001, 74:983–986.
- WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
- Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38 (Suppl 5):S60-S65.
- Stroobants S, Goeminne J, Seegers M, et al.: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec(R)). Eur J Cancer 2003, 39:2012–2020. CrossRef
- Reddy MP, Reddy P, Lilien DL: F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 2003, 28:677–679. CrossRef
- Marsden P, Sutcliffe-Goulden J: Principles and technology of PET scanning. Nucl Med Commun 2000, 21:221–224. CrossRef
- Delbeke D: Oncological applications of FDG PET imaging. J Nucl Med 1999, 40:1706–1715.
- Stokkel MP, Draisma A, Pauwels EK: Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol 2001, 127:278–285. CrossRef
- Young H, Baum R, Cremerius U, et al.: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organisation for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773–1782. CrossRef
- Goerres GW, Stupp R, Barghouth G, et al.: The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005, 32:153–162. CrossRef
- Antoch G, Kanja J, Bauer S, et al.: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45:357–365.
- Choi H, Charnsangavej C, Macapinlac H, et al.: Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate [abstract 3290]. Proc ASCO 2003, 22:819.
- Benjamin RS, Choi H, Charnsangavej C, et al.: We should desist using RECIST, at least in GIST [abstract]. Presented at the Connective Tissue Oncology Society 8th Annual Scientific Meeting. Barcelona Spain, November 6–8, 2003; 40 (abstract 195). This abstract reports the preliminary results of modified CT criteria as a long-term prognostic indicator. The criteria, using a combination of tumor size and density on CT, can discriminate between good and poor responders in GIST patients treated with imatinib while RECIST fails.
- Desai J, Shankar S, Heinrich MC, et al.: Clonal evolution of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions [abstract 3010]. Proc ASCO 2004, 23:197.
- Chen LL, Trent JC, Wu EF, et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64:5913–5919. CrossRef
- Tamborini E, Bonadiman L, Greco A, et al.: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004, 127:294–299. CrossRef
- Wakai T, Kanda T, Hirota S, et al.: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004, 90:2059–2061.
- Demetri G, Benjamin R, Blanke CD, et al.: NCCN Task Force Report: Optimal management of patients with gastrointestinal stromal tumor (GIST)—expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Cancer Network 2004, 2(suppl 1):S1-S26.
- Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model
Current Oncology Reports
Volume 7, Issue 4 , pp 307-311
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Haesun Choi MD (1)
- Author Affiliations
- 1. Department of Radiology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0057, 77030, Houston, TX, USA